Blueprint Medicines Corp (NASDAQ:BPMC) insider Marion Dorsch sold 1,214 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $52.49, for a total value of $63,722.86. Following the completion of the transaction, the insider now owns 16,265 shares of the company’s stock, valued at approximately $853,749.85. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
BPMC traded up $3.18 during trading on Thursday, reaching $60.86. 320,259 shares of the company were exchanged, compared to its average volume of 1,009,835. The company’s 50-day moving average is $58.94 and its two-hundred day moving average is $71.37. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -8.34 and a beta of 1.69. The company has a quick ratio of 4.85, a current ratio of 4.85 and a debt-to-equity ratio of 0.19. Blueprint Medicines Corp has a 12-month low of $43.29 and a 12-month high of $102.98.
Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, February 13th. The biotechnology company reported ($1.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.36. The business had revenue of $51.53 million for the quarter, compared to analysts’ expectations of $26.00 million. Blueprint Medicines had a negative return on equity of 72.52% and a negative net margin of 522.75%. The firm’s quarterly revenue was up 4888.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.83) EPS. Equities analysts forecast that Blueprint Medicines Corp will post -8.63 earnings per share for the current year.
A number of research analysts have issued reports on BPMC shares. BMO Capital Markets upgraded Blueprint Medicines from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $74.00 to $89.00 in a research note on Tuesday, March 17th. Morgan Stanley reduced their price objective on Blueprint Medicines from $108.00 to $103.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. SVB Leerink upped their price target on Blueprint Medicines from $116.00 to $125.00 and gave the company a “positive” rating in a research report on Tuesday, March 17th. HC Wainwright reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Thursday, January 9th. Finally, ValuEngine raised Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, two have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $104.85.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Pictet Asset Management Ltd. increased its stake in Blueprint Medicines by 14.0% in the 3rd quarter. Pictet Asset Management Ltd. now owns 525,982 shares of the biotechnology company’s stock worth $38,644,000 after acquiring an additional 64,532 shares during the last quarter. Eaton Vance Management increased its stake in Blueprint Medicines by 23.5% in the 4th quarter. Eaton Vance Management now owns 215,366 shares of the biotechnology company’s stock worth $17,250,000 after acquiring an additional 41,016 shares during the last quarter. Allworth Financial LP bought a new position in Blueprint Medicines in the 4th quarter worth about $27,000. FMR LLC increased its stake in Blueprint Medicines by 0.3% in the 4th quarter. FMR LLC now owns 7,379,190 shares of the biotechnology company’s stock worth $591,147,000 after acquiring an additional 23,267 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in Blueprint Medicines by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 76,096 shares of the biotechnology company’s stock worth $5,591,000 after acquiring an additional 909 shares during the last quarter. 93.77% of the stock is currently owned by institutional investors and hedge funds.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Recommended Story: What is a Fibonacci Channel?
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.